Display options
Cite
Kumar V, Jain P, Rathore K, et al. Biological Evaluation of Pupalia lappacea for Antidiabetic, Antiadipogenic, and Hypolipidemic Activity Both In Vitro and In Vivo. Scientifica (Cairo). 2016;2016:1062430doi: 10.1155/2016/1062430.
Kumar, V., Jain, P., Rathore, K., & Ahmed, Z. (2016). Biological Evaluation of Pupalia lappacea for Antidiabetic, Antiadipogenic, and Hypolipidemic Activity Both In Vitro and In Vivo. Scientifica, 20161062430. https://doi.org/10.1155/2016/1062430
Kumar, Vivek, et al. "Biological Evaluation of Pupalia lappacea for Antidiabetic, Antiadipogenic, and Hypolipidemic Activity Both In Vitro and In Vivo." Scientifica vol. 2016 (2016): 1062430. doi: https://doi.org/10.1155/2016/1062430
Kumar V, Jain P, Rathore K, Ahmed Z. Biological Evaluation of Pupalia lappacea for Antidiabetic, Antiadipogenic, and Hypolipidemic Activity Both In Vitro and In Vivo. Scientifica (Cairo). 2016;2016:1062430. doi: 10.1155/2016/1062430. Epub 2016 Jan 28. PMID: 26942038; PMCID: PMC4749799.
Copy Download .nbib Format: NLM
Share it on

Scientifica (Cairo). 2016;2016:1062430. doi: 10.1155/2016/1062430. Epub 2016 Jan 28.

Biological Evaluation of Pupalia lappacea for Antidiabetic, Antiadipogenic, and Hypolipidemic Activity Both In Vitro and In Vivo.

Scientifica

Vivek Kumar, Parag Jain, Kalpana Rathore, Zabeer Ahmed

Affiliations

  1. Department of Pharmacology, School of Pharmacy, Babu Banarasi Das University, Lucknow, Uttar Pradesh 226005, India.
  2. Department of Pharmacology, SLT Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh 495334, India.
  3. University Teaching Department, Sarguja University, Ambikapur, Chhattisgarh 497001, India.
  4. Department of Pharmacology, Indian Institute of Integrative Medicine, Jammu, Jammu and Kashmir 180001, India.

PMID: 26942038 PMCID: PMC4749799 DOI: 10.1155/2016/1062430

Abstract

Objective. The present study assesses the effect of Pupalia lappacea (L.) Juss. (Amaranthaceae) (PL) leaves ethanolic extract on adipocytes, blood glucose level, and lipid level in streptozotocin (STZ) induced diabetic rats. Materials and Methods. Male Albino rats were rendered diabetic by a single moderately sized dose of STZ (45 mg/kg, intraperitoneally) at once before starting the treatment. Animals were divided into five groups: normoglycemic control, diabetic control, reference group (glibenclamide, 5.0 mg/kg), AS001 (250 mg/kg extract), and AS002 (500 mg/kg extract) each containing six animals for in vivo study. Antidiabetic and hypolipidemic activity of extract were determined by in vivo method on STZ induced diabetic rats. Antiadipogenic activity was determined by in vitro method on 3T3-L1 cell line in comparison to simvastatin as reference drug. Result. The extract showed significant fall in fasting serum glucose (FSG), that is, 234.68 and 211.61 mg/dL, in STZ induced diabetic animals for dose groups AS001 and AS002, respectively. The PL extract also exhibited noteworthy antiadipogenic activity on 3T3-L1 cell line. The value of inhibitory concentration (IC50) of PL extract to reduce adipocyte cells was found to be 662.14 μg/mL. Conclusion. The PL extract exhibited significant antiadipogenic, antidiabetic, and hypolipidemic activities.

References

  1. Br J Nutr. 1997 Aug;78(2):325-34 - PubMed
  2. Diabetes. 1966 Sep;15(9):675-9 - PubMed
  3. Biochem Biophys Res Commun. 2008 May 9;369(3):969-72 - PubMed
  4. Diabetes. 2006 May;55(5):1407-12 - PubMed
  5. J Endocrinol. 1999 Mar;160(3):409-14 - PubMed
  6. J Ethnopharmacol. 2009 Apr 21;122(3):439-44 - PubMed
  7. Analyst. 1972 Feb;97(151):142-5 - PubMed
  8. J Nutr. 2000 Jan;130(1):15-20 - PubMed
  9. Daru. 2012 Dec 05;20(1):86 - PubMed
  10. Diabetologia. 2005 Mar;48(3):469-76 - PubMed
  11. Clin Chem. 1974 Apr;20(4):470-5 - PubMed
  12. J Nutr. 1998 Dec;128(12):2319-23 - PubMed

Publication Types